Although earlier efforts have used DBS for therapeutic drug monitoring in CML, we are the first to measure and compare DCB and venous blood BCR::ABL1 transcripts [11–13]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.